Vijaya Diagnostic Centre Limited has announced the availability of the audio recording from its earnings conference call for Q3FY26, held on February 13, 2026. The company made this disclosure to stock exchanges on February 14, 2026, in compliance with Regulation 30 requirements.

Earnings Call Details

The earnings conference call was organized following the declaration of the company's unaudited financial results for the third quarter and nine months ended December 31, 2025. The call provided stakeholders with insights into the company's financial performance and business developments during the reporting period.

Accessibility and Availability

The audio recording has been made accessible to investors and stakeholders through multiple channels. The company has provided a direct link to access the recording, which is hosted on their cloud storage platform. Additionally, the recording is available on the company's official website for easy access by interested parties.

The recording can be accessed through the company's investor relations section by following the path: Investors > Results Reports & Presentation > Financial Results > FY 2025-26 > Quarter – III.

Regulatory Compliance

This disclosure was made to both the National Stock Exchange of India Limited and BSE Limited as part of the company's regulatory obligations. The communication was signed by Hansraj Singh, Company Secretary & Compliance Officer, ensuring proper authorization and compliance with corporate governance requirements.

The availability of the earnings call recording demonstrates the company's commitment to transparency and providing stakeholders with comprehensive access to financial information and management commentary on business performance.

Vijaya Diagnostic Centre Limited has announced significant leadership changes and board appointments following its board meeting held on February 13, 2026. The company has strengthened its management team with key appointments across critical functions while also expanding its board with two new independent directors.

Leadership Team Restructuring

The company has appointed three senior executives to key positions effective February 13, 2026. Ankit Shah has been appointed as Chief Financial Officer, bringing over two decades of experience in finance, investment analysis, and healthcare finance. He previously served as Group Chief Financial Officer at Incor Hospitals Private Limited and has extensive expertise in strategic business planning, fundraising, and mergers and acquisitions.

Sai Siva Prasad has been appointed as Chief Technology Officer, bringing over two decades of experience in driving large-scale digital transformation across healthcare, BFSI, IT services, and automotive sectors. He holds a B.Tech in Computer Science and M.Tech from BITS Pilani, along with executive leadership certification from IISc.

Venkata Siva Rama Raju Vegesna has been appointed as Chief Operating Officer. A Chartered Financial Analyst with an MBA in Finance, he previously served as Senior Vice President - Operations at KIMS Hospitals and was earlier associated with Vijaya Diagnostic Centre from 2019 until November 2025.

Board Expansion with Independent Directors

The board has approved the appointment of two new independent directors for a five-year term, subject to shareholder approval. Mr. Ravi Shankararamiah, a Senior Advocate with over four decades of experience in taxation and corporate law, has been appointed as Non-Executive Independent Director. He was designated as Senior Advocate by the High Court of Andhra Pradesh in August 2009.

Dr. Sasikala Paruchuri Kola, a senior Consultant Gynaecologist and Obstetrician with over three decades of experience, has also been appointed as Non-Executive Independent Director. She has held key leadership positions in professional bodies including FOGSI and OGSII.

CFO Transition and ESOP Grant

As part of the organizational restructuring, S. Ramachandra Reddy has stepped down from the CFO position but will continue serving as General Manager - Finance & Accounts. The transition reflects the company's strategic approach to strengthening its leadership structure.

The board has also approved the grant of 1,15,000 Employee Stock Options under the "VDCL Employee Stock Option Plan 2018" at an exercise price of ₹809 per option. These options are convertible into equity shares of face value ₹1 each and will start vesting after one year from the grant date.

Policy Updates

The board has also revised the Policy for dealing in Related Party Transactions based on audit committee recommendations, ensuring continued compliance with regulatory requirements and corporate governance standards.